A coronavirus vaccine developed by Chinese drugmaker Sinopharm is 79% effective in protecting people from the coronavirus, according to interim data released Wednesday by the company Sinopharm. The results for the two-shot vaccine were based on interim analysis from Phase 3 trials.
Knock me over with a feather. Leaders of both parties in Congress look to be near a deal on a $900 billion coronavirus stimulus/relief package with passage possible by the end of the week, the Washington Post is reporting this morning.
Stocks moved higher in the morning today on optimism that the first coronavirus vaccinations meant a “return to normal” was just around the corner. As of 10:00 a.m. Nw York time the Standard & Poor’ 500 had climbed to 3697. And then in the afternoon markets started to worry about news that New York City and California might be headed to a renewed economic lockdown. As of 2:36 p.m. the S&P 500 was back down to 3658.
At 1 p.m. today, November 18, the Standard & Poor’s 500 was up 0.05% and the Dow Jones Industrial Average was ahead 0.06%. Supporting even these meagre gains was positive news from Pfizer that it had concluded trials of its coronavirus vaccine and would be submitting an application for an Emergency Use Authorization to the U.S. Food & Drug Administration within a few days. By the close of the day’s session, however, news of a continuing rise tide of infections and announcements of more closings around the country had extinguished most of the earlier upward momentum.